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Abstract
The yellow fever vaccines (YF-17D-204 and 17DD) are considered to be among the safest vaccines and the presence of
neutralizing antibodies is correlated with protection, although other immune effector mechanisms are known to be
involved. T-cell responses are known to play an important role modulating antibody production and the killing of infected
cells. However, little is known about the repertoire of T-cell responses elicited by the YF-17DD vaccine in humans. In this
report, a library of 653 partially overlapping 15-mer peptides covering the envelope (Env) and nonstructural (NS) proteins 1
to 5 of the vaccine was utilized to perform a comprehensive analysis of the virus-specific CD4+ and CD8+ T-cell responses.
The T-cell responses were screened ex-vivo by IFN-c ELISPOT assays using blood samples from 220 YF-17DD vaccinees
collected two months to four years after immunization. Each peptide was tested in 75 to 208 separate individuals of the
cohort. The screening identified sixteen immunodominant antigens that elicited activation of circulating memory T-cells in
10% to 33% of the individuals. Biochemical in-vitro binding assays and immunogenetic and immunogenicity studies
indicated that each of the sixteen immunogenic 15-mer peptides contained two or more partially overlapping epitopes that
could bind with high affinity to molecules of different HLAs. The prevalence of the immunogenicity of a peptide in the
cohort was correlated with the diversity of HLA-II alleles that they could bind. These findings suggest that overlapping of
HLA binding motifs within a peptide enhances its T-cell immunogenicity and the prevalence of the response in the
population. In summary, the results suggests that in addition to factors of the innate immunity, ‘‘promiscuous’’ T-cell
antigens might contribute to the high efficacy of the yellow fever vaccines.
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Introduction
The yellow fever (YF) vaccines (YF-17D-204 and 17DD) are
considered to be among the most effective vaccines [1,2].
Antibody and T-cell responses are believed to mediate protection
[3,4,5], and recent studies have also implicated the innate
immune responses as one of the critical elements for developing
the immune responses [6]. However, the immune adaptive
mechanisms that make this vaccine so highly effective are
unclear. T-cell immune responses against YF wild type virus and
other flaviviruses, such as dengue and West Nile virus [7,8], are
considered to be important for development of neutralizing
antibodies, and activation of CD4+ helper T-cells and CD8+
cytotoxic T lymphocytes (CTLs) against YF wild type virus has
been reported [6,9,10]. The CTL responses appear 14 days after
vaccination and these cells differentiate into long-lived memory
T-cells after a few months [11]; however, only a few YF wild
type virus T-cell epitopes have been described in humans
[12,13].
In order to expand the repertoire of human leukocyte antigens
(HLA) restricted YF wild type virus epitopes, and as part of the
Immune Epitope Database - IEDB program (http://www.
immuneepitope.org/), we studied the repertoire of T-cell responses
present in a cohort of YF-17DD vaccinees established by Melo et
al. [14] and identified 16 peptides that are immunogenic in more
than 10% of the individuals tested. Analysis of the most prevalent
immunogenic peptides indicated that they contain overlapping
HLA binding motifs and suggested that the prevalence T-cell
immunogenicity in response to YF vaccine (17DD) is correlated
with the ability of the peptide to bind multiple HLA types.
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Materials and Methods
Ethics statement
This study was reviewed and approved by the ethics committee
of the Brazilian Ministry of Health (CONEP: 12138; Process nu
25000.103608/2005-39). In addition, the Johns Hopkins Univer-
sity and University of Pittsburgh Institutional Review Boards also
reviewed and approved this study as protocol JHM-IRB-3: 03-08-
27-01 and PRO09090146 respectively. Written informed consent
was obtained from all volunteers and all clinical investigation was
conducted according to the principles expressed in the Declaration
of Helsinki.
Study Population
A cohort of YF-17DD vaccinees was established and described
elsewhere [14]. Briefly, healthy subjects, IgG-negative for YFV,
were immunized with the YF-17DD vaccine (Biomanguinhos,
Oswaldo Cruz Foundation, Brazil) at The Brazilian National
Health Surveillance Agency (ANVISA) office, International
Airport of Recife. After a full explanation of the study, written
consent was obtained from each volunteer and blood samples were
collected before (Day 0, used as negative controls) and after
vaccination (2 months to 4 years).
Blood Collection and Isolation of Peripheral Blood
Mononuclear Cells (PBMCs)
Blood samples were collected from 220 subjects into 10 mL
VacutainerH tubes (Becton Dickinson, Franklin Lakes, NJ). Serum
was obtained by centrifuging the whole blood at 1,6006g for
10 min and aliquots (1 mL per tube) were stored at 220uC for
further use on serological tests. For harvesting PBMC, blood
samples collected in heparin VacutainerH tubes (Becton Dickinson,
Franklin Lakes, NJ) were used. Isolation of PBMC was carried out
through gradient density using Ficoll-PaqueTM PLUS (Amersham
Biosciences Ab, Uppsala, Sweden) according to the protocol
suggested by the manufacturer. Residual red blood cells were lyzed
with Ammonium-Chloride-Potassium lysing buffer (Gibco BRL,
Gaithersburg, MD) for 3 min at room temperature. Then, cells
were resuspended in Hybridoma Serum Free Media (SFM; Gibco
BRL, Gaithersburg, MD) for ELISPOT assaying.
CD4+ T-Cell Depletion
PBMC samples from at least 3 subjects, known to respond
against the peptides Env57–71, Env345–359, Env361–375, NS3137–151,
NS4b77–91, NS5341–355, NS5345–359, NS5465–479 and NS5481–495
were depleted of CD4 T-cells using anti-CD4 mAb coated
microbeads (Miltenyi Biotec, Auburn, CA) and LD columns
(Miltenyi Biotec, Auburn, CA) according to manufacturer’s
directions. This approach consistently yielded cell samples in
which depletion was greater than 95% for CD4+ T-cells,
according to flow cytometry analysis (data not shown).
Isolation of CD8+ T-Cells
CD8+ T-cells were isolated from PBMC samples by the negative
selection method using the isolation kits and LS columns provided
by Miltenyi Biotec (Auburn, CA), according to the manufacturer’s
manual. This approach consistently yielded cell samples in which
purity was greater than 90% for CD8+ T-cells according to flow
cytometer analysis (data not shown).
Peptide Library
To measure the breadth and magnitude of T-cell responses, a
library of 653 peptides (15-mers), overlapping by 11 amino acids,
spanning the length of the 17DD YFV proteins Env (n = 120), NS1
(n = 47), NS2a (n = 32), NS2b (n = 28), NS3 (n = 148), NS4a
(n = 45), NS4b (n = 17) and NS5 (n = 216) (sequence NCBI entry
U17066) was synthesized by Schafer-N (Copenhagen, Denmark).
These peptides were HPLC-purified to 80% purity or greater,
with the exception of four peptides that could not be purified and
were used as crude products.
The Env peptides were pooled in groups of 6 peptides, totalizing
20 pools, Box S1. NS peptides were arranged into matrix pools
[NS1 (767); NS2a (864); NS2b (764); NS3 (15610); NS4a (865);
NS4b (464) and NS5 (17613)] ensuring that each peptide was
present in two different pools, Box S2 [15]. Ten NS peptides were
tested individually (no pooling).
The peptides NS4b77–85, NS4b76–84, NS4b75–83, NS4b75–84
were synthesized and purified by Genescript (New Jersey, USA).
The purity of these peptides was greater than 95%.
Stock solutions of all peptides were sterile-prepared at 2 mg/mL
in 10% (v/v) dimethil sulphoxide (DMSO; Sigma-Aldrich) and
stored at 220uC until use.
Cell Lines and Peptide Pulsing
Transporter associated with antigen processing-deficient T2
cells expressing HLA-A*0201 were maintained in RPMI 1640
medium (Invitrogen, Brown Dee, WI) supplemented with 10% (v/
v), fetal bovine serum (FBS; Hyclone, Logan, UT), 1% (v/v)
glutamine (Gibco, Gaithersburg, MD) and 1% (v/v) penicillin-
streptomycin (Gibco, Gaithersburg, MD). For pulsing the peptides,
one million target cells were washed, resuspended in 1 mL of
media and incubated at 37uC for 2 h with peptides at 10 mg/mL.
Cells were then washed 3 times and resuspended in SFM at 16106
cells/mL for T-cell function assays.
ELISPOT Assay for IFN-c
Interferon-c ELISPOT assays were performed by using the
ELISPOT set from BD-Biosciences Pharmingen (San Diego, CA),
according to the manufacturer9s protocol. Briefly, 96-well nitro-
cellulose-bottom plates were coated with 100 mL/well primary
antibody anti-human IFN-c at 5 mg/mL and incubated at 4uC
Author Summary
T-cell responses are considered to be very important;
however, the role of T-cell responses in vaccine mediated
immunity is still controversial. One reason may be that
most studies of human T-cell responses are focused on a
few epitopes. We still lack a systematic view of the
repertoire of peptides presented by the different HLA class
I and II molecules and how the peptides presented by the
different HLAs interact within the host to develop T-cell
responses. Here we present a study of the T-cell responses
against the YF-17DD vaccine in the context of a cohort of
220 volunteers and observed that the most prevalent T-cell
responses are targeted at peptides that bind to multiple
types of HLA molecules. Based on these results we
postulate that promiscuous T-cell epitopes might have a
critical role in the development of adaptive immunity.
These results may have broader implications for other
pathogens, since the yellow fever vaccine is currently
being developed as a vaccine vector for other diseases.
Therefore, these epitopes might have a functionally
cooperative role in boosting specific neutralizing antibody
responses. In addition, we propose that promiscuous T-cell
antigens may be better immunogens for vaccine devel-
opment; however more studies are necessary.
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overnight. The following day, plates were blocked with 200 mL/
well of RPMI 1640 (Invitrogen, Brown Dee, WI) containing 10%
(v/v) heat-inactivated FBS (Hyclone, Logan, UT), 1% (v/v)
glutamine (Gibco, Gaithersburg, MD) and 1% (v/v) penicillin-
streptomycin (Gibco, Gaithersburg, MD) for 2 h at room
temperature. Then, the cells were plated, in duplicate, at a range
of 1–36105 cells/well along with peptides at 10 mg/mL (concen-
tration of each peptide when tested as a pool and also the
concentration of individual peptides when tested individually) both
in SFM. During peptide pool analysis and deconvolution, total
PBMC were used as source of T-cells. For the experiments aimed
to confirm whether CD8+ T-cells were driving the cellular
responses, in addition to total PBMC, CD4-depleted PBMC
samples were included in the analysis. Media (SFM) containing
1% (v/v) glutamine, 1% (v/v) penicillin-streptomycin alone
(background) and media supplemented with phorbol 12-myristate
13-acetate (PMA; Sigma) at 250 ng/mL and ionomycin (Sigma) at
250 ng/mL were used as negative and positive controls, respec-
tively. After 16 h incubation at 37uC, 5% CO2, the plates were
washed twice with distilled water and 4 times with PBS containing
0.05% Tween-20 (PBS-T; Sigma) followed by incubation for 2 h,
at room temperature, with 4 mg/mL of biotinylated anti-human
IFN-c. Plates were again washed four times with PBS-T and
incubated for 1 h, at room temperature, with avidin-horseradish
peroxidase at 10 mg/mL. After another washing cycle (56) using
PBS-T followed by three washes with PBS, plates were developed
with substrate 3-amino-9-ethyl carbazole (AEC; BD-Biosciences
Pharmingen, San Diego, CA) for 40 min. The reaction was
stopped with distilled water, the plates were air-dried and spots
were counted using the ImmunoSPOT reader using Immuno-
SPOT software version 3.2 (Cellular Technology Ltd.). Totals for
duplicated wells were averaged and normalized to numbers of
IFN-c spot forming cells (SFC) per 16106 PBMCs.
In experiments aimed at confirm the HLA-A*0201 restriction of
T-cell epitopes identified, ELISPOT was performed using T2 cell
lines as target to activate CD8+ T-cells. T2 cells were pulsed with
each of the NS4b peptides (NS4b77–85, NS4b76–84, NS4b75–83 and
NS4b75–84) individually. Peptide-pulsed target cells and effector
cells (CD8 T-cells) were co-cultured at 16105 cells/well each and
incubated for 16 h at 37uC, 5% CO2 on ELISPOT plate. After
incubation, the cells were removed and IFN-c was detected as
described above. The negative controls were effector cells only and
effector cells plated with unpulsed target cells, whereas the positive
control was PMA/ionomycin as mentioned previously.
The criteria to identify positive peptide pools/individual
peptides relied on the combination of the following equations: (i)
mean number of spots (peptides)22 standard deviations
(SD).mean number of spots (background); (ii) mean number of
spots (peptides).mean number of spots (background)+2 SD; (iii)
mean number of spots (peptides) - mean number of spots
(background).10. The peptide pools that met all criteria listed
above were directly selected. For the NS proteins, T-cell responses
among volunteers analyzed during pool analysis was low and, thus,
difficult to comply with the analysis criteria shown above;
therefore, an additional test was applied in order to increase the
number of pools to deconvolute. This additional test consisted of
the calculation of a cut-off based on average (Avg) SFC of the top
25% peptide pool and standard error through the following
equation: Avg SFC Top 25% peptide pool +2 SE. The peptide pool in
which SFC value was greater than the cut-off was also considered
positive. The combinations in which the frequency was greater
than 7% (for NS1 and NS3 peptides); 10% (for NS2a, NS2b, NS4a
and NS4b); and 16% to NS5 were taken into account, and their
respective common peptide was selected to be tested individually.
HLA Genotyping
Genomic DNA was extracted from PBMCs collected from 142
volunteers by using the PureLink Genomic DNA MiniKit
(Invitrogen, Carlsbad, CA) following the manufacturer protocol.
HLA alleles genotyping was performed using the polymerase chain
reaction (PCR) test sequence-specific primer (SSP) UniTray Kit
(Invitrogen, Brown Dee, WI), which provides low to intermediate
HLA typing results according to the manufacturer protocol. After
amplification, the PCR products were separated in 2% (w/v)
agarose gel pre-stained with ethidium bromide (0.25 mg/mL gel).
Gels were electrophoresed for 30 min at 150 volts in 0.56Tris-
Boric acid-EDTA (TBE) buffer, then examined under Ultraviolet
illumination and documented by photography. The types of HLA-
A, B, C were then determined by specific electrophoresis bands
using the UniMatch Software (Invitrogen, Brown Dee, WI).
Further analysis was performed to determine the HLA allele in
high-resolution for the individuals HLA-A*02 positives using the
same methodology above mentioned.
Artificial APC (aAPC) Loading and Expansion of NS4b-
Specific CD8 T-Cells
The peptides NS4b77–85, NS4b76–84, NS4b75–83 and NS4b75–84
were incubated individually with HLA-A*0201/anti-hCD28
aAPCs [16,17,18] at concentration of 506106 beads/mL for 5
days at 4uC. Then, one million CD8+ T-cells isolated from HLA-
A*0201 positive individuals were co-cultured with 16106 of each
peptide-loaded aAPCs, individually, in RPMI 1640 media
supplemented with 8% (v/v) T-cell growth factor (TCGF) and
5% (v/v) human AB serum. On day 4, the plates were replenished
with media containing TCGF and AB human serum and cultured
for 3 more days. On day 7, the aAPCs were removed and the cells
were washed, counted and their concentration adjusted to 16106
cells/mL in RPMI 1640 media (Invitrogen, Brown Dee, WI)
supplemented with 10% (v/v) FBS (Hyclone, Logan, UT).
Intracellular Cytokine Staining (ICS) to Detect NS4b-
Specific CD8+ T-Cell Responses
CD8+ T-cells (16105) that underwent one round of expansion
with different aAPCs were ‘‘challenged’’ with T2 cells (16105)
pulsed, individually, with each NS4b peptides for 2 h at 37C, 5%
CO2. Then, Golgi stop (BD Biosciences, San Diego, CA) was
added to the culture to stop protein trafficking and secretion. The
cells were cultured for 4 h at 37C, 5% CO2 and then washed twice
with staining buffer [PBS containing 0.05% sodium azide and 2%
(v/v) FBS (Hyclone, Logan, UT)]. The cells were stained with anti-
CD8 FITC (Sigma Aldrich, St. Louis, MO) for 20 min at 4uC and
washed 3 times with staining buffer. After that, the cells were
permeabilized with cytoperm/cytofix buffer (BD Biosciences, San
Diego, CA) for 20 min at 4uC followed by 3 washes with perm/
wash buffer (BD Biosciences, San Diego, CA). Then staining with
either anti-hCD107a-PE (BD Biosciences, San Diego, CA) or anti-
hIFN-c-PE (BD Biosciences, San Diego, CA) was performed for
30 min at 4uC, after which the cells were washed twice with perm/
wash buffer and once with staining buffer. Finally, the cells were
acquired on a FACS Calibur flow cytometer (BD Bioscience, San
Diego, CA) and the data was analyzed using Flowjo for Macintosh
version 8.8.6 (Tree star, Ashland, OR).
MHC Purification and Binding Assays
Purification of HLA class II MHC molecules by affinity
chromatography, and the performance of assays based on the
inhibition of binding of a high affinity radiolabeled peptide to
quantitatively measure peptide binding, were performed essential-
YFV-17DD Elicits Promiscuous T-Cell Responses
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ly as detailed elsewhere [19,20,21,22,23]. Briefly, EBV trans-
formed homozygous cell lines were used as sources of MHC
molecules. A high affinity radiolabeled peptide (0.1–1 nM) was co-
incubated at room temperature or 37C with purified MHC in the
presence of a cocktail of protease inhibitors. Following a two-day
incubation, MHC bound radioactivity was determined by
capturing MHC/peptide complexes on Ab coated Lumitrac 600
plates (Greiner Bio-one, Frickenhausen, Germany), and measuring
bound cpm using the TopCount (Packard Instrument Co.,
Meriden, CT) microscintillation counter. The concentration of
peptide yielding 50% inhibition of the binding of the radiolabeled
peptide was calculated. Under the conditions utilized, where
[label],[MHC] and IC50$[MHC], the measured IC50 values
are reasonable approximations of the true Kd values. Each
competitor peptide was tested at six different concentrations
covering a 100,000-fold range, and in three or more independent
experiments. As a positive control, the unlabeled version of the
radiolabeled probe was also tested in each experiment.
Statistical Analysis
Fisher’s two-tailed test was used to associate the response against
a given peptide and HLA genotype. When significant p-values
were achieved (p,0.05), the odds ratio and 95% confidence
intervals (CI) were calculated (R Statistical Package 2.9.0). HLA-
A, B and C genotype distributions were checked with Hardy-
Weinberg equilibrium. In addition, we compared the allelic
distributions of the five genotyped HLA genes (HLA-A, HLA-B,
HLA-C, HLA-DR, HLA-DQ) to HLA genotype data obtained
from the MHC Database (dbMHC) of the NCBI, consisting of two
studies with Brazilian populations: one with volunteers from the
state of Minas Gerais (which we refer to as ‘‘dbMHC1’’), and
another with volunteers from the state of Sa˜o Paulo (referred to as
‘‘dbMHC2’’). Pearson’s correlation was used to assess the co-
variation between HLA promiscuity and frequency of recognition
of the yellow fever T-cell epitopes identified.
Results
Screening of Immunogenic Peptides
The immunogenicity of the YF-17DD peptides was determined
by IFN-c ELISPOT performed ex vivo using PBMCs from
immunized volunteers. A flowchart summarizing the assays and
strategies for characterization of the T-cell responses are show in
Figure 1. Blood samples were negative for anti-YF-17DD
antibodies prior to vaccine inoculation and all vaccinees serocon-
verted by one month after immunization [14]. The peptides were
organized in groups corresponding to the Env, NS1, NS2, NS3,
NS4 and NS5 proteins and screened in two rounds. In the first
round the peptides were organized in pools or matrices and tested
in samples from a series of donors as indicated in Table 1. In the
second round, immunogenic peptides were selected from the pools
screened individually as indicated in Table 2.
Screening of immunogenic T-cell peptides within the structural
proteins: The initial screening was performed with 120 peptides
from the Env protein. The peptides were organized in 20 pools
with six peptides in each and tested in samples from 146
volunteers. Five pools (3, 9, 14, 15 and 20) were immunogenic
in 13 to 34 of the 146 individuals tested. Peptide pool number 15
was immunogenic in 34 of the 146 individuals tested and was most
prevalent immunogenic pool in this population (data not shown).
Thirty individual peptides from these five pools were selected for a
second round of analysis and tested individually (Table 2).
Thirteen peptides were positive in the second round (Table S1).
Six (Env57–71, Env65–79, Env73–87, Env337–351, Env345–359 and
Env361–375) out of the 30 Env peptides tested individually were
positive in at least 10% the volunteers. Their protein position,
amino acid sequence, frequency with in the cohort and magnitude
of the ex vivo T-cell response are shown on Table 3.
Screening of immunogenic T-cell peptides within Non-struc-
tural (NS) proteins. A similar strategy was applied to screen the T-
cell responses against NS peptides. In the first round, the pools
were organized in matrices with each peptide being present in two
pools to allow identification of the immunogenic peptide within
each pool. The matrices were assembled as described in the
methods section and tested in a series of samples from different
volunteers (Table 1). The peptide pool matrix analysis, in many
cases, allowed the precise identification of the immunogenic
peptide within each pool. The peptides that most frequently
activated T-cell responses in the individuals tested are shown in
Table S1. These peptides were selected for the second round of
screening as individual peptides in a second set of samples. The
summary of the results of the second round is shown in Table 2. In
total, 7 (NS1), 3 (NS2a), 6 (NS2b), 18 (NS3), 11 (NS4a), 2 (NS4b)
and 13 (NS5) peptides were shown to be immunogenic on 1 to 11
vaccinees tested in the second round (Table S1). Ten peptides
among NS proteins (NS2b97–111, NS2b113–127, NS3137–151,
NS4a197–211, NS4b77–91, NS5341–355, NS5345–359, NS5465–479,
NS5469–483, NS5481–495) were immunogenic in at least 10% of
the YF-17DD vaccinees. Their position, sequence, frequency and
magnitude of T-cell response are shown on Table 3.
Identification of HLA Class I Alleles Associated with the
Most Frequently Immunogenic Peptides
In order to investigate the HLA restriction related to the T-cell
responses to each of the peptides shown on Table 3, HLA
genotyping was performed for the loci HLA-A, HLA-B and HLA-
C on 142 YF-17DD vaccinees (Table S2). The frequency of the
HLA types present in our cohort was compared to the frequencies
reported by two Brazilian blood banks (Minas Gerais -
‘‘dbMHC1’’ and Sa˜o Paulo - ‘‘dbMHC2’’) and deposited at the
cohort dbMHC database. Statistical analysis indicated a large
degree of correlation between the HLA diversity present in the
study volunteers and the ones on the dbMHC database, for all
available genes (p,0.01), suggesting that the HLA diversity of the
cohort is representative of the general Brazilian population. The
HLA types of the samples used on the second round of screening
and the respective peptide with which they reacted are shown in
Table S3. Subsequently, we investigated the possibility of some
HLA types to be overrepresented among the individuals respond-
ing to a peptide. Indeed, some HLA types were very prevalent
among the responders of some peptides. For example, HLA-A*23
was very frequent among the individuals responding to the
NS5481–495 peptide while it was seldom observed among individ-
uals that did not react to this peptide suggesting the possibility that
this HLA type might be involved in the presentation of an epitope
present within the immunogenic 15-mer. In order to confirm these
associations, Fisher’s test was carried out comparing the frequency
of the HLA types present in the vaccinees responding to a given
peptides versus the HLA frequency in the general population or
among the ones that did not respond. The HLA alleles with
significant statistical associations are shown in Table 4.
Nine out of the 16 immunogenic peptides could be statistically
associated with one or more HLA type. Seven peptides presented
significant associations with one HLA type, four HLA-A (A*02,
A*11, A*23, A*26), three HLA-B (B*15, B*18, B*39) and one
HLA-C (C*12). Two peptides, Env361–375 and NS5341–355 showed
significant association with two HLA-types (A*26 and B*18) and
(B*39 and C*12) respectively. Three immunogenic peptides
YFV-17DD Elicits Promiscuous T-Cell Responses
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Env57–71, Env345–359 and NS4b77–91, were associated with HLA-
A*02 and other two NS5341–355 and NS5345–359 were associated
with B*39. However these two peptides associated with B*39
overlap by 11 amino acids suggesting that these associations are
likely directed to an immunogenic determinants shared by these
two adjacent peptides.
Figure 1. Screening of immunogenic yellow fever peptides. Blood samples were obtained from 220 vaccinees. 653 peptides from Env and
non-structural proteins were organized in pools and tested by ELISPOT assay. Then, 108 immunogenic peptides were selected from the pools and
tested individually. In total, 16 peptides were positive in at least 10% the subjects. Statistical association showed that nine immunogenic peptides
were associated with HLA class-I. Seven from these peptides could activate CD4+ depleted PBMCs from YF-17DD vaccinees ex vivo. In addition, 9–10
mers peptides covering the NS4b77–91 were cultured in CD8
+ T-cells isolated from HLA-A*02:01-positive individuals. Four epitopes (NS4b77–85,
NS4b75–83, NS4b75–84, NS4b76–84) were able to induce a specific response. Biochemical binding assays indicated that the most prevalent immunogenic
peptides could bind multiple HLA-II molecules.
doi:10.1371/journal.pntd.0001938.g001
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Validation of HLA Class I Association Strategy and
Confirmation of HLA-A*02 CD8+ T-Cell-Restricted
Responses
The peptides Env57–71, Env345–359 and NS4b77–91 induced
immune responses predominantly in HLA-A*02 individuals
(Tables 4 and S3). In addition, the statistical analysis indicated
that the peptides Env361–375, NS3137–151, NS5341–355, NS5345–359,
NS5465–479 and NS5481–495 were associated with the presence of
the other HLA class I alleles. In order to validate these
associations, we analyzed whether CD8+ T-cells derived from
the immunized individuals could be activated by these peptides.
For these analysis, PBMCs from 3 volunteers were collected, the
CD4+ T-cell depleted, and the T-cell responses to each peptide
measured by ELISPOT. It is important to note that some antigen
presenting cells (APC) were unintentionally removed, because
CD4 is also expressed on monocytes and dendritic cells, albeit at
lower levels than on CD4+ T helper cells. Seven of the nine
peptides selected could activate CD4+ depleted PBMCs from YF-
17DD vaccinees ex vivo, whereas PBMCs collected pre-vaccination
were negative, corroborating the hypothesis that these immune
responses are likely being mediated by CD8+ T-cells (Table 5).
In order to further determine the HLA-restriction involved on the
T cell response against the peptide NS4b77–91, previously shown to
be associated with HLA-A*02, all the subjects bearing this HLA
were genotyped at high resolution for this locus.. According to the
analysis, 78% of the subjects responding against the peptide
NS4b77–91 were HLA-A*02:01 (Table S3). Subsequently, all the 9-
mers covering the NS4b77–91 sequence were synthesized and tested
for T-cell activation on PBMC from HLA-A*0201 subjects (n = 3
per peptide). For this experiment, the initial 15-mer was used as
positive control. Among the 9-mers derived from the NS4b77–91, the
NS4b77–85 (LWNGPMAVS) was the one that induced the most T-
cell activation (NS4b77–91, used as positive control in Figure 2C).
Interestingly, Akondy et al. [24] identified an immunodominant
epitope HLA-A*02-restricted on NS4b protein of YF-17D vaccine,
the position of which was at amino acid 76–84 (LLWNGPMAV),
one amino acid to N-terminal side (Figure 2A). This observation
highlights one important caveat of screening peptide libraries, and
points at the presence of epitopes not detected due to the manner in
which the 15-mer peptides of the library were spliced. Therefore, we
tested the adjacent peptide at the position 75–91 for the presence of
potential HLA-A*02:01-restricted epitopes within its sequence.
Since these peptides have a common core (LWNGPMA), they
would represent possible products of antigen processing that could
activate the same T cell clone. Thus, to investigate that these
peptides could be presented by HLA-A*02:01, CD8+ T-cells were
isolated from HLA-A*02:01-positive individuals and the ELISPOT
assay for IFN-c was performed using T2 cells, which expresses
HLA-A*02:01 exclusively, as target for T-cell activation. Figure 2B
depicts representative ELISPOT data set. All peptides analyzed
could activate CD8+ T-cells, but to different degrees. The peptides
with the core LLWNGPMAV (NS4b76–84 and NS4b75–84) induced
the highest number of spots, whereas the peptides in which the core
was incomplete (NS4b77–85 and NS4b75–83) the T-cell response
tended to be lower. Finally, we tested the ability of these peptides to
expand the population of CD8+ T-cells of the patients for one week
using aAPC loaded with each of the NS4b peptides. One million
purified CD8 T-cells were co-cultured with each aAPC (ratio 1:1)
and after one week the yield of cellular proliferation of the CD8+ T-
cell population expanded by the aAPCs loaded with NS4b77–85,
NS4b76–84, NS4b75–83 or NS4b75–84 peptides were 2610
6, 46106,
2.56106 and 3.56106 respectively, indicating a proliferation of 2 to
4 fold. Flow cytometry analysis showed that after one week of
expansion, epitope-specific CD8+ T cells were activated, as
degranulating cells (surface CD107a; data not shown) producing
IFN-c (Figure 2C) were identified upon challenging with the same
epitopes used during cell expansion. Notably, the expansion of
NS4b76–84-specific CD8
+ T-cells was the highest among the
peptides tested and reached 22%. Interestingly, the peptide
NS4b75–84, which on unexpanded CD8
+ T-cells tested ex vivo
elicited comparable levels of T-cell response as NS4b76–84, had,
after one week expansion with the aAPC, a frequency of NS4b75–84
specific-CD8+ T-cells that was 4-fold less as compared to NS4b76–84.
These results suggest that there might be different products of
antigen processing that could potentially be activating the same T
cell clone, however at different degrees. The physiological role of
these products of antigen processing for an effective T cell response
needs to be further investigated.
Analysis of HLA Class II Responses
CD4+ and CD8+ responses cooperate with each other,
enhancing and also regulating T-cell responses. CD4+ T-cell
helper cytokine responses are required for a proper activation of
Table 1. Summary of screening peptide pools (first round).
Protein No. of peptides No. vaccinees
No. of peptides
recognized
Env 120 146 20*
NS1 47 29 30
NS2a 32 52 27
NS2b 28 52 25
NS3 148 29 61
NS4a 45 52 38
NS4b 17 52 17
NS5 216 37 192
The table shows a list of all yellow fever proteins mapped, total number of
peptides tested for each protein (No. of peptides), volunteers (No. vaccinees)
and peptides into a pool that were positive at least one subject (No. of peptides
recognized).
*Env peptide pools. Twenty peptide pools were positive at least one subject.
doi:10.1371/journal.pntd.0001938.t001
Table 2. Summary of screening individual peptides (second
round).
Protein No. of peptides No. vaccinees No. of peptides recognized
Env* 30 62 13
NS1 9 46 7
NS2a 3 59 3
NS2b 6 59 6
NS3 18 46 18
NS4a 17 59 11
NS4b 4 59 2
NS5 21 48 13
The table shows a list of all yellow fever proteins mapped, total number of
individual peptides tested (No. of peptides), volunteers (No. vaccinees) and
individual peptides that were positive at least one subject (No. of peptides
recognized).
*The most immunogenic Env pools (3, 9, 14, 15 e 20) were selected and thirty
peptides (six peptides in each pool) were tested individually.
doi:10.1371/journal.pntd.0001938.t002
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naı¨ve CD8+ T-cells [25] and CD4+ helper epitopes linked to each
other can also cooperate to allow more efficient T-cell priming of
weaker epitopes [26,27]. Thus, it is reasonable to expect that the
most immunogenic peptides could contain both HLA-I and HLA-
II binding motifs. Therefore to address this, the binding affinity of
the immunogenic peptides was determined for 14 different HLA
class II molecules (DRB1*0101, 0301, 0401, 0404, 0405, 0701,
0802, 0901, 1101, 1302, 1501, DRB3*0101, DRB4*0101,
DRB5*0101) and the results are shown in Table 6. All the
peptides tested could bind with high affinity (IC50#1000 nM, see
[28]) to at least one HLA-DR molecule. Levels of peptide
promiscuity varied from low (affinity to 2 to 5 HLA class II
molecules bound), e.g. NS5341–355 and NS5345–359; to intermediate
(affinity to 6 to 9 HLA class II molecules bound), e.g. Env337–351,
NS2b97–111 and NS5465–479; and highly promiscuous (binding to
$10 HLA molecules), e.g. Env57–71, Env345–359, NS4b77–91,
NS5469–483, and NS5481–495. Nine peptides (Env57–71, Env345–359,
Env361–375, NS3137–151, NS4b77–91, NS5341–355, NS5345–359,
NS5465–479 and NS5481–495) contained overlapping HLA-I an
HLA-II binding motifs (Tables 3 and 6). This suggested that our
screening process targeted the identification of promiscuous T-cell
antigens. We then tested whether the frequency of recognition of
the peptides on the cohort was dependent on the level of
promiscuity of those to different HLA-II molecules. There was a
significant correlation (R2 = 0.45, p = 0.01) between the number of
HLA class II molecules bound to the peptides (Figure 3) and the
frequency of positivity in the vaccinees, suggesting that the
prevalence of the immunogenicity of an antigen in the population
is associated with the HLA promiscuity of the T-cell antigen.
Table 3. Most frequent peptides that activated T-cells from YF-17DD vaccinees.
Peptide Sequence (n) 2nd round
No. of
responders
Recognition
frequency (%)
Average ±
STDEV
Median
(peptide)
Median (negative
control)
Env57–71 RKVCYNAVLTHVKIN 30 10 33 1496248 48 2
Env65–79 LTHVKINDKCPSTGE 30 3 10 1586196 83 5
Env73–87 KCPSTGEAHLAEENE 30 3 10 1466153 60 2
Env337–351 ADDLTAAINKGILVT 18 3 17 23610 28 3
Env345–359 NKGILVTVNPIASTN 27 9 33 72685 30 3
Env361–375 DEVLIEVNPPFGDSY 27 4 15 72688 35 9
NS2b97–111 VVMTSLALVGAALHP 59 6 10 1466 12 4
NS2b113–127 ALLLVLAGWLFHVRG 22 3 14 80689 43 2
NS3137–151 GTSGSPIVNRNGEVI 46 5 11 90649 115 5
NS4a197–211 TMLSPMLHHWIKVEY 22 3 14 1406178 61 3
NS4b77–91 LWNGPMAVSMTGVMR 59 11 19 1006138 50 3
NS5341–355 RMAMTDTTPFGQQRV 48 6 12 92693 52 5
NS5345–359 TDTTPFGQQRVFKEK 48 8 17 3366320 172 3
NS5465–479 EFGKAKGSRAIWYMW 48 6 12 4866707 67 2
NS5469–483 AKGSRAIWYMWLGAR 48 8 17 3956643 45 3
NS5481–495 GARYLEFEALGFLNE 48 11 23 3836380 204 2
(n) =Number of volunteers tested against each individual peptide.
doi:10.1371/journal.pntd.0001938.t003
Table 4. Statistical HLA class I association analysis.
Peptide HLA Association
Env57–71 A*02 (OR = 3; p = 0.03)
Env345–359 A*02 (OR = 5; p = 0.003)
Env361–375 A*26 (OR = 9; p = 0.03)
B*18 (OR = 10; p = 0.01)
NS3137–151 A*11 (OR = 3; p = 0.03)
NS4b77–91 A*02 (OR = 3; p = 0.02)
NS5341–355 B*39 (OR = 13; p = 0.004)
C*12 (OR = 8; p = 0.006)
NS5345–359 B*39 (OR = 9; p = 0.01)
NS5465–479 B*15 (OR = 5; p = 0.04)
NS5481–495 A*23 OR= 6; p = 0.001
doi:10.1371/journal.pntd.0001938.t004
Table 5. Determination of memory CD8 T-cell-restricted
responses against the peptides associated with HLA class I
molecules.
Peptide
No. of
responders
IFN-c SFC (CD4-depleted PBMCs/
106)
Average ± STDEV Median
Env57–71 3 1526145 84
Env345–359 3 3156160 287
Env361–375 2 1660 16
NS3137–151 0 - -
NS4b77–91 3 101623 101
NS5341–355 0 - -
NS5345–359 3 66671 32
NS5465–479 2 16860 168
NS5481–495 2 9560 95
(2) = No response.
doi:10.1371/journal.pntd.0001938.t005
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Discussion
This study presents the screening of 653 peptides of the YF-
17DD Env, NS1, NS2, NS3, NS4 and NS5 proteins in the context
of a cohort of healthy adults immunized with the YF-17DD
vaccine. Considering the two rounds of peptide screening, each
peptide was tested in at least 75 individuals, and in the case of the
Env protein each peptide was tested in 208 volunteers. The
Figure 2. YF-17DD Immunodominant HLA-A*0201 restricted epitope in the NS4b protein. A. Sequences of the peptides used to identify
the immunogenic nonamer epitope in NS4b. IC50 values for IEDB-AR prediction were calculated; B. PBMCs from HLA-A2 vaccinees were cultured in
the presence or absence of 9–10mer (NS4b77–85, NS4b76–84, NS4b75–83, NS4b75–84) peptides. ELISPOT assay; C. Intracellular cytokine staining were
performed. All peptides analyzed could activate CD8+ T-cells and the expansion of NS4b76–84-specific CD8
+ T-cells was the highest among the four
peptides tested. Plots gated on CD8+ T-cells for one representative donor are shown.
doi:10.1371/journal.pntd.0001938.g002
Table 6. Binding affinity in nanomols of the most frequent peptides that activated T-cells.
Peptide DRB1 DRB3 DRB4 DRB5 Total
*0101 *0301 *0401 *0404 *0405 *0701 *0802 *0901 *1101 *1302 *1501 *0101 *0101 *0101
DR
bound
Env57–71 242 2579 219 1104 459 57 423 457 938 123 1846 197 306 7.4 11
Env337–351 31 956 1795 5614 11918 32 846 68 1228 0.23 63 119 1243 853 9
Env345–359 41 386 0.73 716 189 33 3.5 281 24 4.2 8.1 2756 23 401 13
Env361–375 335 100 7.0 911 387 1563 21 4314 2574 30 566 267 578 6789 10
NS2b97–111 3.9 19386 3664 4258 23 60 222 69 6739 7214 987 9903 1183 64 7
NS3137–151 7356 18002 - - - - 19010 15842 9476 36 6310 9292 - 7162 1
NS4b77–91 181 84 202 2814 1329 303 348 307 2810 62 575 852 317 1281 10
NS5341–355 1834 650 201 - 11772 20 1343 11624 - 2270 12683 4835 478 9533 4
NS5345–359 2837 6737 5694 319 180 5420 - - - - 9072 3551 4800 7393 2
NS5465–479 72 5988 884 1198 1186 53 2388 428 4721 2637 450 1043 417 537 7
NS5469–483 26 5088 2788 380 289 247 424 699 4183 1919 202 440 98 513 10
NS5481–495 30 627 951 2898 73 40 7484 81 5925 10577 299 22 255 80 10
Total Peptides bound 9 6 7 4 7 9 7 8 2 6 8 6 8 7
Population Frequency (%) 9,17 7,33 13,33 - - 14,33 6,00 1,17 10,67 15,67 13,00 - - -
Numbers in bold: values of IC50 below the cutoff of 1000 nmol by which determine that the peptide has affinity to the HLA molecule.
(2): not determined.
doi:10.1371/journal.pntd.0001938.t006
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screening allowed the identification of 16 T-cell peptides that were
immunogenic in 10% or more of the individuals tested. Only a few
YF-17D epitopes have been characterized previously [12,13,24].
Overall, among the 16 immunogenic peptides identified herein, 14
contain new human T-cell antigens (Env57–71, Env65–79, Env73–87,
Env337–351, Env345–359, Env361–375, NS2b97–111, NS3137–151,
NS4a197–211, NS5341–355, NS5345–359, NS5465–479, NS5469–483,
NS5481–495). Two peptides, NS2b113–127 [12] and the NS4b77–91
[24], contained epitopes previously described in humans, while the
Env57–71 and NS2b113–127 peptides contain epitopes that have
been described in the murine H2d background. The murine
epitope (Env57–71) was reported to be able to stimulate both CD8
+
and CD4+ T-cells to secrete IFN-c in YF-17DD vaccine
immunized H2 d mice and also HLA A02, B07 and A24
transgenic mice [29,30]. These highly prevalent immunogenic
peptides were shown to contain multiple HLA binding motifs and
that the degree of prevalence of its immunogenicity was correlated
with the HLA promiscuity. Previous studies have shown some
degree of correlation between predicted binding affinity and
immunogenicity [30]. However, additional studies are required to
determine the precise breath and differences in functionalities of
these immunogenic peptides in different HLA contexts.
Biochemical binding assays indicated that the most prevalent
immunogenic peptides could bind multiple HLA molecules and
the prevalence of their immunogenicity was correlated with the
presence of multiple HLA binding motifs. Interestingly, the level of
promiscuity of the class II binding was correlated with the
prevalence of the immunogenicity of the peptide in the cohort
(Figure 2).
No promiscuous T-cell immunogens (peptides that bind more
than one HLA allelic variant) have been described for YF wild
type virus or other flaviviruses until now. Computational strategies
for determination of promiscuous HLA-I and II binding peptides
[28,31] have been used for cancer [32] and infectious disease [33].
Besides the theoretical advantage of being broadly reactive in the
population, the biological characteristics of promiscuous T-cell
epitopes are not clear and only few promiscuous epitopes have
been identified.
CD4+ T-cells play a major role in the generation of CD8+
cytotoxic T-cell responses and maturation of neutralizing anti-
bodies [34,35,36]. In addition, virus-specific CD4+ T-cells may be
able to tolerate more sequence diversity in their target epitopes
than CD8+ T-cells, thus being more resistant to mutational escape
[37]. Most of the immunogenic peptides, subsequently assessed
using competitive binding assays bound to at least six HLA-DR
alleles, indicating that an individual bearing at least one such
HLA-DR molecule could develop broad CD4+ T-cell responses
against the YF-17DD. Previous work has shown that many
peptides are capable of binding with good affinity to multiple DR
alleles [19,28,38,39,40]. However, it is still not clear how a given
promiscuous peptide binds different HLA class II molecules. For
example, Kilgus et al. [41] showed that distinct sites on the malaria
T-cell epitope interact in different ways with the three DR
molecules analyzed [41]. On the other hand, Panina-Bordignon et
al. [42] showed that promiscuous peptides interact in a similar way
with different DR molecules, possibly by binding to the conserved
DR residues [42]. Chicz et al. [43] suggested that the ability of
peptides to bind multiple HLA alleles must be dependent on the
composition and location of several key amino acids within the
primary structure, which led to the hypothesis that rigid allele-
specific motifs for the class II molecule do not exist, thus
permitting a broad binding specificity [43]. To our knowledge,
the present study is the first report showing that the frequency of
recognition of the peptides is dependent on the level of promiscuity
of those to different HLA molecules. The exact role of the
promiscuous peptides in protective immune response still un-
Figure 3. Correlation analysis. The results of ELISPOT and biochemical binding assays indicated that the level of promiscuity of the class II binding
was correlated with the prevalence of the immunogenicity of the peptide in the yellow fever cohort.
doi:10.1371/journal.pntd.0001938.g003
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known, however one would expect that a vaccine built with
multiple immunodominant promiscuous epitopes, capable to bind
several HLA molecules, could lead to an increased coverage of the
human population. Although the cellular and humoral responses
play a central role in effectiveness of YF vaccines, the innate
immunity, which is known to shape the development of adaptive
immune responses, also contribute to vaccine-mediated protection
through other mechanisms, including its live replicative nature and
its ability to trigger several Toll-like receptors [6]. In conclusion,
the identification of this set of highly prevalent class I and II T-cell
epitopes will enable detailed studies of the role of T-cell responses
on the development of yellow fever immunity and the identifica-
tion of the structural requirements of immunogenic promiscuous
T-cell epitopes.
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